Clinical Trial

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2025 (before its estimated November 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. \[Time Frame: 3 months\] Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis. Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-21; most recent amendment 2025-03-17.
Trial Details
NCT Number NCT06283498
Lead Sponsor InMode MD Ltd.
Conditions Overactive Bladder Syndrome
Enrollment 32 participants
Start Date 2023-11-10
Primary Completion 2025-11-10 (estimated)
Study Completion 2027-11-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-18